Mateo et al. found that deleterious ATM mutations in metastatic prostate cancer were associated with good response to olaparib, a PARP inhibitor that is approved for the treatment of several solid tumors in the European Union [35, 53]. This evidence concerns the gene ATM and metastatic prostate carcinoma.